Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components and functions of PDCs for therapeutic, from drug target screening and PDC design improvement strategies to clinical applications to improve the permeability, targeting, and stability of the various components of PDCs. This holds great promise for the future of PDCs, such as bicyclic peptide‒toxin coupling or supramolecular nanostructures for peptide-conjugated drugs. The mode of drug delivery is determined according to the PDC design and current clinical trials are summarised. The way is shown for future PDC development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Hennrich, U., & Kopka, K. (2019) · Pharmaceuticals · doi:10.3390/ph12030114 · Cited by 440
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
68Ga-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer
Zhang, J., Mao, F., Niu, G., Peng, L., Lang, L., Li, F., Ying, H., Wu, H., Pan, B., Zhu, Z., et al. (2018) · Theranostics · doi:10.7150/thno.22601 · Cited by 95
Recent Trends in Nanotechnology Toward CNS Diseases
Cardoso, A. M., Guedes, J. R., Cardoso, A. L., Morais, C., Cunha, P., Viegas, A. T., Costa, R., Jurado, A., & Pedroso de Lima, M. C. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.05.002 · Cited by 26
Yamada, Y., Yabe, D., Hertz, C. L., Horio, H., Nakamura, J., Nielsen, A. M., & Seino, Y. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14571 · Cited by 21
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Antibody–drug conjugates: Recent advances in payloads
Wang, Z., Li, H., Gou, L., Li, W., & Wang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.015 · Cited by 264
Metadata
- Authors
- Fu, C., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 13
- Issue
- 2
- Pages
- 498-516
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W4289528601
- Cited by
- 209
- References
- 6
- FWCI
- 11.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? https://app.cochat.ai/papers/10.1016/j.apsb.2022.07.020
- The paper
- Fu, C., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2023). Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2022.07.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.